The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
Stopping finasteride may reduce water retention or alter fat distribution, leading to a leaner face. Hormonal changes, like reduced DHT or increased estrogen, could cause these effects.
A user experienced puffy nipples and lumps from finasteride, leading to a dilemma between continuing treatment with potential surgery or accepting hair loss. They restarted finasteride at a lower dose with supplements but still face side effects and are seeking advice on whether to persist or stop.
The user is experiencing chest sensitivity and muscle ache after using topical finasteride for a month and is concerned about potential gynecomastia. They are considering asking their doctor for blood work to check estrogen levels and are questioning whether to stop using finasteride.
The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.
A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.
AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.
The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.
The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.
The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.
The user is considering switching from finasteride to RU-58841 for hair loss due to side effects and is concerned about its safety around cats. They are also seeking dosage suggestions and alternatives like pyrilutamide.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.